{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:18:57Z","timestamp":1794287937447,"version":"4.9.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021201","name":"European Academy of Dermatology and Venereology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021201","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.omtn.2026.103088","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:45:26Z","timestamp":1788479126000},"page":"103088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Distinct responses of COL17A1 nonsense variants to readthrough drugs and NOG as a novel enhancer in junctional epidermolysis bullosa"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7208-4319","authenticated-orcid":false,"given":"Yan","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5581-8078","authenticated-orcid":false,"given":"Haifa","family":"El Mabrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-2039","authenticated-orcid":false,"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8804-2965","authenticated-orcid":false,"given":"Sato","family":"Magassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-507X","authenticated-orcid":false,"given":"Cristina","family":"Has","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-3494","authenticated-orcid":false,"given":"Saliha Beyza","family":"Sayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103088_bib1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.omtn.2026.103088_bib2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s13555-024-01227-8","article-title":"Treatment of Epidermolysis Bullosa and Future Directions: A Review","volume":"14","author":"Danescu","year":"2024","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.omtn.2026.103088_bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40257-021-00626-3","article-title":"Investigational Treatments for Epidermolysis Bullosa","volume":"22","author":"Hou","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.omtn.2026.103088_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ymthe.2025.10.054","article-title":"Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosa","volume":"34","author":"Hierl","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103088_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.976604","article-title":"COL17A1 editing via homology-directed repair in junctional epidermolysis bullosa","volume":"9","author":"Petkovi\u0107","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.omtn.2026.103088_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fmed.2018.00363","article-title":"Junctional Epidermolysis Bullosa: Allelic Heterogeneity and Mutation Stratification for Precision Medicine","volume":"5","author":"Condrat","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.omtn.2026.103088_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jid.2021.09.018","article-title":"Read-Through for Nonsense Mutations in Type XVII Collagen\u2012Deficient Junctional Epidermolysis Bullosa","volume":"142","author":"Has","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2026.103088_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5483\/BMBRep.2023-0190","article-title":"Nonsense-mediated mRNA decay, a simplified view of a complex mechanism","volume":"56","author":"Carrard","year":"2023","journal-title":"BMB Rep."},{"key":"10.1016\/j.omtn.2026.103088_bib9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","article-title":"Quality and quantity control of gene expression by nonsense-mediated mRNA decay","volume":"20","author":"Kurosaki","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2026.103088_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s12964-025-02503-6","article-title":"Nonsense-mediated mRNA decay: a key regulatory system engaged in cancer","volume":"23","author":"Pan","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.omtn.2026.103088_bib11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/cells14151215","article-title":"Therapeutic Opportunities in Overcoming Premature Termination Codons in Epidermolysis Bullosa via Translational Readthrough","volume":"14","author":"Miao","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2026.103088_bib12","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.3390\/ijms21124394","article-title":"Suppression of Nonsense Mutations by New Emerging Technologies","volume":"21","author":"Morais","year":"2020","journal-title":"IJMS"},{"key":"10.1016\/j.omtn.2026.103088_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15042","article-title":"Stop codon readthrough as a treatment option for epidermolysis bullosa\u2014Where we are and where we are going","volume":"33","author":"Zandanell","year":"2024","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.omtn.2026.103088_bib14","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.353","article-title":"Nonsense Suppression Therapy: An Emerging Treatment for Hereditary Skin Diseases","volume":"102","author":"Yu","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.omtn.2026.103088_bib15","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.jid.2024.02.027","article-title":"Strategy for the Optimization of Read-Through Therapy for Junctional Epidermolysis Bullosa with COL17A1 Nonsense Mutation","volume":"144","author":"Sayar","year":"2024","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2026.103088_bib16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1039\/C003962D","article-title":"Comparative quantitation of proteome alterations induced by aging or immortalization in primary human fibroblasts and keratinocytes for clinical applications","volume":"6","author":"Sprenger","year":"2010","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.omtn.2026.103088_bib17","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.jid.2017.05.011","article-title":"Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa","volume":"137","author":"Atanasova","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.omtn.2026.103088_bib18","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamadermatol.2023.2077","article-title":"Treatment With Ataluren for Wound Healing and Health Complications in a Patient With Junctional Epidermolysis Bullosa","volume":"159","author":"Orlowski","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.omtn.2026.103088_bib19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ymthe.2020.03.006","article-title":"Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations","volume":"28","author":"Kwong","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103088_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102334","article-title":"Novel readthrough agent suppresses nonsense mutations and restores functional type VII collagen and laminin 332 in epidermolysis bullosa","volume":"35","author":"Levian","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103088_bib21","doi-asserted-by":"crossref","first-page":"E6536","DOI":"10.1073\/pnas.1803154115","article-title":"Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa","volume":"115","author":"Lincoln","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103088_bib22","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1111\/1346-8138.15230","article-title":"Gentamicin induces COL17A1 nonsense mutation readthrough in junctional epidermolysis bullosa","volume":"47","author":"Li","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.omtn.2026.103088_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102368","article-title":"Reading through the nonsense: Gentamicin and ELX-02 as rescuing therapies for epidermolysis bullosa","volume":"35","author":"Anderson-Crannage","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103088_bib24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000513260","article-title":"Drug Development for Target Ribosomal Protein rpL35\/uL29 for Repair of LAMB3R635X in Rare Skin Disease Epidermolysis Bullosa","volume":"34","author":"Rathner","year":"2021","journal-title":"Skin Pharmacol. Physiol."},{"key":"10.1016\/j.omtn.2026.103088_bib25","doi-asserted-by":"crossref","DOI":"10.1553\/skindeep.2025.169584","article-title":"Treating severe junctional epidermolysis bullosa with artesunate","volume":"1","author":"Sinz","year":"2025","journal-title":"skinonline."},{"key":"10.1016\/j.omtn.2026.103088_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100240","article-title":"En Route to Targeted Ribosome Editing to Replenish Skin Anchor Protein LAMB3 in Junctional Epidermolysis Bullosa","volume":"4","author":"Wimmer","year":"2024","journal-title":"JID Innov."},{"key":"10.1016\/j.omtn.2026.103088_bib27","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41467-020-15140-z","article-title":"2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations","volume":"11","author":"Trzaska","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103088_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1261\/rna.060236.116","article-title":"The nucleoside analog clitocine is a potent and efficacious readthrough agent","volume":"23","author":"Friesen","year":"2017","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2026.103088_bib29","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s10495-016-1273-y","article-title":"Clitocine potentiates TRAIL-mediated apoptosis in human colon cancer cells by promoting Mcl-1 degradation","volume":"21","author":"Sun","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.omtn.2026.103088_bib30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.molcel.2013.12.028","article-title":"Optimal Translational Termination Requires C4 Lysyl Hydroxylation of eRF1","volume":"53","author":"Feng","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omtn.2026.103088_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3002355","article-title":"Nonsense mutation suppression is enhanced by targeting different stages of the protein synthesis process","volume":"21","author":"Wittenstein","year":"2023","journal-title":"PLoS Biol."},{"key":"10.1016\/j.omtn.2026.103088_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/jmg.2010.086751","article-title":"Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa","volume":"48","author":"Kiritsi","year":"2011","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.omtn.2026.103088_bib33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2340\/00015555-3133","article-title":"A Silent COL17A1 Variant Alters Splicing and Causes Junctional Epidermolysis Bullosa","volume":"99","author":"Hoffmann","year":"2019","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/j.omtn.2026.103088_bib34","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1038\/s41467-024-46703-z","article-title":"Extended stop codon context predicts nonsense codon readthrough efficiency in human cells","volume":"15","author":"Mangkalaphiban","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103088_bib35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/biom11071006","article-title":"Stop Codon Context-Specific Induction of Translational Readthrough","volume":"11","author":"Schilff","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.omtn.2026.103088_bib36","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52611","article-title":"Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides","volume":"9","author":"Wangen","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.omtn.2026.103088_bib37","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.103088_bib38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2\u2212\u0394\u0394CT Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:15:53Z","timestamp":1793632553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2162253126002593"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103088","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct responses of COL17A1 nonsense variants to readthrough drugs and NOG as a novel enhancer in junctional epidermolysis bullosa","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103088"}}